Florian Eichhorn
YOU?
Author Swipe
Impact of Combined Additional Resections on the Surgical Outcomes of Robot‐Assisted Resection of Thymic Epithelial Tumors Open
Background and Objectives Robot‐assisted thoracoscopy (RATS) is rapidly emerging as the preferred approach for the resection of thymic epithelial tumors (TET). Current challenges include the role of RATS in locally advanced disease and com…
View article: Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial Open
Background The phase II NEOMUN trial was conducted to investigate the therapeutic effect of preoperative programmed death receptor-1 inhibitor pembrolizumab for treating non-small cell lung cancer (NSCLC). Herein, we report the final effic…
Image analysis: 68Ga-FAPI-46 PET derived texture parameters improve the differentiation of malignant and benign pulmonary lesions Open
Background Pulmonary lesions inconclusive in 18 F-FDG PET/CT are a known clinical problem. Both texture analysis and 68 Ga-FAPI-46 have shown potential in thoracic oncological problems but their combination has not been assessed yet. This …
Impact of the number of involved lymph node zones on survival in stage IIIA-N2 lung adeno and squamous cell carcinoma Open
OBJECTIVES The role of upfront surgery in treating stage IIIA-N2 non-small cell lung cancer remains controversial. This study aimed to evaluate the role of upfront surgery in selected patients with stage IIIA-N2 and assess the prognostic s…
Robot‐Assisted Versus Open Surgery for the Resection of Large Thymomas: A Retrospective Cohort Study Open
Background Robot‐assisted thoracic surgery (RATS) is increasingly becoming the preferred surgical method for the resection of thymomas. We initiated the current study to evaluate perioperative outcomes and early recurrence associated with …
View article: NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study Open
Background Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional block…
View article: Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy
Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy Open
Tumor organoids are important tools for cancer research, but current models have drawbacks that limit their applications for predicting response to therapy. Here, we developed a fast, efficient, and complex culture system (IPTO, individual…
Impact of T Cell Ratios on Survival in Pleural Mesothelioma: Insights from Tumor Microenvironment Analysis Open
Background: Immunotherapy has significantly improved overall survival in patients with pleural mesothelioma, yet this benefit does not extend to those with the epithelioid subtype. Tumor growth is believed to be influenced by the immune re…
Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients Open
MALAT1, GAS5, and calretinin could be potential biomarkers for the prediction of tumor recurrence, improving the benefit from multimodal treatment including cytoreductive surgery.
Diagnostic Potential of Supplemental Static and Dynamic<sup>68</sup>Ga-FAPI-46 PET for Primary<sup>18</sup>F-FDG–Negative Pulmonary Lesions Open
PET using 68Ga-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) holds high potential for diagnostic imaging of various malignancies, including lung cancer (LC). However, 18F-FDG PET is still the clinical gold standard for LC …
Thoracic surgery in the non-intubated spontaneously breathing patient Open
Background The interest in non-intubated video-assisted thoracic surgery (NIVATS) has risen over the last decade and numerous terms have been used to describe this technique. They all have in common, that the surgical procedure is performe…
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors Open
Introduction PD-(L)1 inhibitors (IO) have improved the prognosis of non-small-cell lung cancer (NSCLC), but more reliable predictors of efficacy and immune-related adverse events (irAE) are urgently needed. Cytokines are important effector…
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach Open
EPD/HITOC is feasible and safe for localized epithelioid pleural mesothelioma. Changing the surgical approach to a less radical lung-sparing technique may improve overall survival compared to trimodal EPP.
Surgical Lung Biopsy for Interstitial Lung Disease: A Two Center Propensity Score Matching Analysis Open
Background: Surgical lung biopsy (SLB) is recommended for patients with nonclassified interstitial lung disease (nILD) if high resolution computed tomography and/or transbronchial lung biopsy did not achieve a definitive diagnosis. Current…
Sarcopenia on preoperative chest computed tomography predicts cancer‐specific and all‐cause mortality following pneumonectomy for lung cancer: A multicenter analysis Open
Background Mortality risk prediction in patients undergoing pneumonectomy for non‐small cell lung cancer (NSCLC) remains imperfect. Here, we aimed to assess whether sarcopenia on routine chest computed tomography (CT) independently predict…
Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma Open
Background Large-cell neuroendocrine lung carcinoma (LCNEC) is a rare pulmonary neoplasm with poor prognosis and limited therapeutic options. Methods We retrospectively analyzed all patients with metastatic LCNEC in the records of a large …
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis Open
The programmed death-ligand 1 (PD-L1) plays a crucial role in immunomodulatory treatment concepts for end-stage non-small cell lung cancer (NSCLC). To date, its prognostic significance in patients with curative surgical treatment but regio…
How to handle oligometastatic disease in nonsmall cell lung cancer Open
Patients with nonsmall cell lung cancer and limited metastatic disease have been defined as oligometastatic if local ablative therapy of all lesions is amenable. Evidence from different clinical retrospective series suggests that this subg…
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer Open
Background: Epidermal growth factor receptor-mutated (EGFR + ) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging. Methods: …
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes Open
Subtyping of non-small cell lung cancer (NSCLC) is paramount for therapy stratification. In this study, we analyzed the largest NSCLC cohort by mass spectrometry imaging (MSI) to date. We sought to test different classification algorithms …
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer Open
Reliable entity subtyping is paramount for therapy stratification in lung cancer. Morphological evaluation remains the basis for entity subtyping and directs the application of additional methods such as immunohistochemistry (IHC). The dec…
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial Open
Prospectively, the NEOMUN study has been registered on www.clinicaltrials.gov ; NCT03197467 (first post: June 23rd, 2017).
Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma Open
Particle radiotherapy (PRT, CIRT) showed superior OAR sparing and optimal target volume coverage. The observed dosimetric advantages are expected to reduce toxicity rates. However, their clinical impact must be investigated prospectively.
Spatial distribution of <i>EGFR</i> and <i>KRAS</i> mutation frequencies correlates with histological growth patterns of lung adenocarcinomas Open
Multiregional analysis provided first indications for morphological and molecular heterogeneity in lung adenocarcinomas (ADCs), but comprehensive morpho‐molecular comparisons are still lacking. The purpose of our study was to investigate t…
Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer Open
Non-evident somatic mitochondrial mutations and highly varying mitochondrial DNA level delineate challenges for the approach of mitochondria-targeted anticancer therapies in NSCLC.